Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387813 · ClinicalTrials.gov registry record · NA
Hemodynamic-GUIDEd Management of Heart Failure
A NA study of Heart Failure and Heart Failure, Congestive, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,358
- Enrollment target
- 20
- Study locations
NCT03387813: Completed NA study of Heart Failure and Heart Failure, Congestive, sponsored by Abbott Medical Devices.
NCT03387813 is a NA study of Heart Failure and Heart Failure, Congestive that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,358 participants, above the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03387813, a NA study of Heart Failure and Heart Failure, Congestive, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
Primary Outcome
The composite of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of heart failure (HF) emergency department/hospital outpatient observation visits for intravenous diuretic therapy (ED/OP) 3. The number of deaths of any cause added together with equal weighting into a total number of events
Conditions Studied
Interventions
- DEVICE CardioMEMS™ HF System
Study Locations (20)
California
- John Muir Medical Center - Concord
- Adventist Health St. Helena - Deer Park
- Scripps Health - La Jolla
- University of California at San Diego (UCSD) Medical Center - La Jolla
- USC University Hospital - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Eisenhower Medical Center - Rancho Mirage
- Sutter Medical Center, Sacramento - Sacramento
- Mercy Medical Group - Cardiology - Sacramento
- San Diego Cardiac Center - San Diego
- California Pacific Medical Center - Van Ness Campus - San Francisco
- Ventura Cardiology Consultants - Ventura
Arizona
- Banner-University Medical Center Phoenix - Phoenix
- Arizona Cardiovascular Research Center - Phoenix
- Phoenix Cardiovascular Research Group - Phoenix
- University of Arizona - Tucson
Arkansas
- Washington Regional Medical Center - Fayetteville
- Baptist Health Medical Center - Little Rock
- Arkansas Heart Hospital - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,358 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-05-17 |
| Phase | NA |
What the finished NCT03387813 record still lists
NCT03387813 is an interventional study that assigns participants to a tested intervention. Its 2,358 participants enrollment target places it among the larger protocols in the corpus, above the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target (15% higher).
The record links to 10 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CardioMEMS™ HF System is the first listed.
NCT03387813 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03387813 about?
NCT03387813 is a clinical study titled "Hemodynamic-GUIDEd Management of Heart Failure". The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
What is the current status of trial NCT03387813?
This trial is currently completed. It is a NA study. The enrollment target is 2,358 participants. The study started on 2018-03-15. Estimated completion is 2023-05-17.
What conditions does trial NCT03387813 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure, Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure, Diastolic, Heart Failure, Systolic.
What interventions are being tested in trial NCT03387813?
The interventions under investigation include: CardioMEMS™ HF System (DEVICE).
Who is sponsoring clinical trial NCT03387813?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03387813 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03387813's enrollment target sits among peer trials
2,358 39th of 397 higher than 359 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00025935 · 2,350 participants
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
- NCT03099850 · 2,345 participants
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI